Research Tools & Consumables Stocks Q1 Results: Benchmarking Danaher (NYSE:DHR)
The article reviews the Q1 earnings of research tools & consumables stocks, highlighting mixed results across the sector. Danaher (NYSE:DHR) reported revenues slightly below expectations, leading to an 11.4% stock decline. In contrast, Waters Corporation (NYSE:WAT) significantly outperformed, while Revvity (NYSE:RVTY), Thermo Fisher (NYSE:TMO), and Avantor (NYSE:AVTR) also presented varying financial outcomes and market reactions.
Revvity Stock: Analyst Estimates & Ratings
Revvity, Inc. (RVTY), a health sciences solutions provider, has underperformed the broader market and a healthcare ETF over the past year and year-to-date. Despite this, the company reported strong Q1 results with a 5% EPS increase, and analysts forecast 5.3% EPS growth for the current fiscal year, leading to a "Moderate Buy" consensus rating among analysts. The mean price target suggests an 18.1% premium to its current price.
Revvity declares $0.07 dividend
Revvity has declared a quarterly dividend of $0.07 per share, payable on August 9, 2023, to shareholders of record as of July 19, 2023. The ex-dividend date is July 18, 2023. This announcement follows the company's previous dividend payments and indicates its ongoing commitment to returning value to shareholders.
Revvity stock (US76155R1086): diagnostics specialist in focus after latest earnings and life-science
Revvity Inc. (US76155R1086), a diagnostics and life-science tools specialist, is highlighted after its latest quarterly earnings and ongoing strategic shift. The company, which emerged from PerkinElmer's rebranded life-science and diagnostics activities, focuses on recurring revenue from reagents, services, and software, alongside instrument sales. This article details Revvity's core business model, key revenue drivers, competitive position, and relevance for US investors, emphasizing its exposure to long-term trends in healthcare and scientific innovation.
Revvity secures FDA clearance for total testosterone immunoassay
Revvity has received FDA 510(k) clearance for its total testosterone immunoassay. This new assay is designed to provide accurate and reliable testosterone measurements across a wide physiological range, aiding in the diagnosis and management of conditions related to testosterone imbalance in both men and women. The clearance marks a significant step for Revvity in expanding its diagnostic offerings.
Revvity stock (US76155R1086): life science player after Q1 update and new AI lab tools
Revvity Inc. has released its Q1 2026 figures and is continuing to expand its life science tools portfolio, which now includes AI-enabled lab software. The company focuses on diagnostics and life science tools, offering instruments, reagents, diagnostic solutions, and lab software. For US investors, Revvity provides exposure to precision diagnostics, biopharma research, and lab digitalization, with a business model centered on recurring revenue.
Immunovant director Atul Pande sells $192,000 in shares
Immunovant director Atul Pande sold $192,000 worth of company common stock on May 20, 2026, after exercising stock options. The transactions were conducted under a Rule 10b5-1 trading plan. Immunovant shares have seen a 147% surge over the last year, despite the company remaining unprofitable.
Q1 Earnings Highlights: Sotera Health Company (NASDAQ:SHC) Vs The Rest Of The Research Tools & Consumables Stocks
This article analyzes the Q1 2026 earnings for Sotera Health Company (NASDAQ:SHC) and compares its performance to other research tools & consumables stocks. It highlights Waters Corporation as the top performer with significant revenue growth, while Revvity showed the weakest performance against analyst estimates. The piece also briefly touches on broader market shifts from AI and crypto anxieties to geopolitical risks influencing investment decisions.
Revvity Inc. stock (US76155R1086): investors weigh latest earnings and diagnostics focus
Revvity Inc. recently released its quarterly financial results, providing insights into its revenue mix, profitability, and future outlook for its diagnostics and life-science tools portfolio. The company specializes in diagnostics, life-science tools, and related software solutions, focusing on technologies that aid disease detection, laboratory workflows, and scientific discovery. Revvity Inc. plays a significant role for US investors by offering exposure to the broader life-science tools and diagnostics segment, influenced by domestic healthcare utilization, reimbursement policies, and research funding trends.
There May Be Some Bright Spots In Revvity's (NYSE:RVTY) Earnings
This article analyzes Revvity's upcoming earnings, noting that while the company has generally performed in line with expectations, a significant portion of its sales comes from COVID-related products, which could pose future risks. Despite this, positive analyst revisions suggest there may be favorable aspects to its financial outlook. Investors will be observing whether Revvity can maintain its growth trajectory post-COVID and manage its debt effectively.
There May Be Some Bright Spots In Revvity's (NYSE:RVTY) Earnings
Despite soft profit numbers, Revvity's recent earnings report was well-received by the market, potentially due to promising signs beyond statutory figures. The company's profit was reduced by US$95m due to unusual items, which are not expected to recur, suggesting higher future profits. Investors are encouraged to look beyond the surface-level earnings and consider the impact of these one-off events.
Revvity's (NYSE:RVTY) Conservative Accounting Might Explain Soft Earnings
Despite a soft earnings report, Revvity's stock remained strong, possibly due to investors focusing on positive factors beyond the numbers. The company's profit was reduced by US$95 million due to unusual items, which are generally not repeated and could lead to higher profits next year if they don't recur. This suggests Revvity's statutory profit may currently understate its true earnings potential.
Revvity secures FDA clearance for total testosterone immunoassay
This article mentions that Revvity has secured FDA clearance for its total testosterone immunoassay. No further details are available in the provided content.
Revvity stock (US76155R1086): Q1 earnings beat and guidance set the tone
Revvity Inc. (US76155R1086) reported stronger-than-expected Q1 2026 earnings per share of $1.06, surpassing the consensus estimate of $1.02. The company also issued full-year guidance for EPS between $4.85 and $4.95 and revenue between $2.8 billion and $2.9 billion, largely aligning with market expectations. Despite some stock volatility, Revvity's core business model in life sciences tools and diagnostics leverages recurring revenue from consumables and services, aiming for stable growth in a dynamic industry.
Revvity (RVTY) Is Down 5.0% After Raising 2026 Outlook And Securing FDA Assay Clearance
Revvity, Inc. (RVTY) experienced a 5.0% stock decline despite reporting stronger-than-expected first-quarter sales of US$711.12 million, raising its 2026 revenue outlook to US$2.81–US$2.84 billion, and securing FDA clearance for a Total Testosterone immunoassay. The company aims to balance modest top-line growth with a shift towards higher-margin offerings, capitalizing on demand for advanced diagnostics and reproductive health testing while navigating risks like reimbursement pressures in China. Despite the positive developments, the stock's downturn suggests investor caution regarding ongoing market challenges and diverse analyst perspectives on future growth.
Revvity stock (US76155R1086): FDA assay clearance, outlook to 2026 and fresh collaboration momentum
Revvity Inc. has updated its multi-year outlook, reporting strong first-quarter 2026 revenues and raising its full-year 2026 revenue guidance. The company also secured FDA clearance for a Total Testosterone automated immunoassay and announced a collaboration around its Revvity Signals platform, signaling strategic advancements in diagnostics and data-driven research. Despite positive developments, the stock experienced a slight dip, reflecting a cautious market sentiment in the life-science tools sector.
Revvity Inc. stock outperforms competitors on strong trading day
Revvity Inc. (RVTY) shares advanced 1.61% to $95.48 on Monday, outperforming the mixed trading session where the Dow Jones Industrial Average rose and the S&P 500 Index fell. The stock closed 19.29% below its 52-week high of $118.30, achieved on January 22nd. The article details Revvity's performance relative to major market indices.
Revvity, Inc. (RVTY): Investor Outlook Reveals 20.94% Potential Upside In Healthcare Innovation
Revvity, Inc. (RVTY) is attracting investor attention in the healthcare sector, particularly in diagnostics and research, with a market capitalization of $10.48 billion. Analysts project a 20.94% potential upside, driven by the company's strategic rebranding, robust financial fundamentals including a 7.00% revenue growth rate, and diverse product portfolio. While the dividend yield is modest, the conservative payout ratio signals reinvestment into innovation and growth, positioning Revvity as a promising long-term investment in a dynamic industry.
Revvity (RVTY) Is Down 5.0% After Raising 2026 Outlook And Securing FDA Assay Clearance
Revvity (RVTY) dropped 5.0% despite reporting stronger-than-expected first-quarter sales of US$711.12 million, raising its 2026 revenue outlook to US$2.81–US$2.84 billion, and securing FDA clearance for a Total Testosterone immunoassay. The new FDA clearance is particularly relevant as it expands Revvity's offerings in endocrine and reproductive health, supporting recurring consumables revenue, although the company still faces risks from reimbursement pressures in China and funding weakness in academic and government markets. Analysts project Revvity's revenue to reach $3.3 billion and earnings to hit $599.9 million by 2028, with a fair value of $119.56, representing a 27% upside to its current price.
Revvity stock (US76155R1086): steady diagnostics player after latest quarterly update
Revvity, a life science and diagnostics company, recently updated its quarterly figures, highlighting modest growth in core diagnostics and life science tools, alongside a focus on margin improvement. The company's business model relies on recurring revenue from consumables and services for clinical laboratories and research facilities, providing resilience in its revenue streams. Investors monitor Revvity for exposure to healthcare, biotechnology, and analytical technology trends, balancing recurring revenue potential with cyclical capital equipment budgets and competitive pressures.
Revvity stock (US76155R1086): collaboration momentum and diagnostics focus after recent share move
Revvity (RVTY) has gained investor attention after a nearly 5% stock increase following its collaboration with Eli Lilly to expand access to predictive models via the Revvity Signals platform. The company, which specializes in life sciences tools and diagnostics, focuses on providing instruments, consumables, reagents, and software for drug discovery, clinical diagnostics, and applied testing. This overview highlights Revvity's business model, key revenue drivers, recent share performance, and competitive position within the evolving healthcare and life sciences sectors.
Assessing Revvity (RVTY) Valuation After Recent Share Price Weakness
Revvity (RVTY) has experienced recent share price weakness, with the stock down 2.5% over the past day and 7% over the past week, prompting a re-evaluation of its valuation. While Simply Wall St's narrative suggests the stock is 21.4% undervalued with a fair value of $119.56 due to expected margin expansion and a shift towards higher-margin offerings, its current P/E ratio is significantly above fair value and industry averages. Investors are encouraged to consider both the discounted cash flow model suggesting a 31.8% discount and the high P/E ratio when making decisions.
A Look At AbCellera Biologics (ABCL) Valuation As ABCL-635 Advances Into Phase II Trials
AbCellera Biologics (ABCL) has advanced its lead program, ABCL-635, into Phase II trials, leading to renewed interest and a significant increase in its share price over the past year. Despite a recent short-term decline, the stock is currently trading at a steep discount to the average analyst price target, although its P/S ratio is considerably higher than industry and peer averages. The company's valuation narrative suggests it is undervalued, supported by strong liquidity and future operational efficiencies.
Revvity stock (US76155R1086): T. Rowe Price reports a 9% stake
T. Rowe Price Associates has disclosed a 9.0% passive stake in Revvity Inc. (NASDAQ: RVTY), a Nasdaq-listed health-care tools company specializing in diagnostics and life-science research. This institutional filing provides a new angle for U.S. investors monitoring the company, indicating continued confidence from a large asset manager. Revvity's stock is often watched for stability in consumables and resilience in research demand, as its revenue is tied to clinical diagnostics, life-science research, and applied testing.
Revvity Inc. stock underperforms Friday when compared to competitors
Revvity Inc. (RVTY) stock fell 2.50% on Friday, closing at $93.97, while the broader market also experienced a downturn. The company's stock underperformed compared to its competitors and closed 20.57% below its 52-week high of $118.30. The S&P 500 Index and Dow Jones Industrial Average also recorded declines for the day.
FDA OKs Revvity’s Total Testosterone Assay
Revvity, through its subsidiary Immunodiagnostic Systems (IDS), has received U.S. FDA 510(k) clearance for its Total Testosterone automated chemiluminescence immunoassay (ChLIA). This new assay completes Revvity's solution for testosterone-related disorders, allowing direct ChLIA measurements of total testosterone, SHBG, and free testosterone on a single platform. The company states it streamlines workflow and diagnostic testing for conditions like hypogonadism without compromising accuracy, replacing more complex methods.
T. Rowe Price (RVTY) discloses 10.1M-share, 9.0% stake in Revvity
T. Rowe Price Associates, Inc. has filed an amended Schedule 13G/A, revealing a beneficial ownership of 10,097,663 shares, or 9.0%, of Revvity Inc. common stock. The filing indicates that T. Rowe Price holds sole voting power over 10,019,315 shares and sole dispositive power over all 10,097,663 shares, positioning them as a significant passive institutional holder. While the firm denies being the beneficial owner, a common practice when managing client accounts, this update provides insight into their substantial, non-controlling investment in Revvity.
Analysts Conflicted on These Healthcare Names: Cullinan Management (CGEM), Humacyte (HUMA) and Revvity (RVTY)
Healthcare analysts have issued conflicting ratings for several companies. David Dai from UBS maintained a Buy rating for Cullinan Management (CGEM), while Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating for Humacyte (HUMA). In contrast, Michael Ryskin from Bank of America Securities maintained a Hold rating on Revvity (RVTY).
Rising revenue but cash risk at VolitionRx (NYSE: VNRX) in Q1 2026
VolitionRx (NYSE: VNRX) reported Q1 2026 revenues of $985,076 and a net loss of $6.7 million, with an operating cash outflow of $5.3 million, leaving $3.1 million in cash. The company faces "substantial doubt" about its ability to continue as a going concern due to recurring losses, negative cash flows, and significant liabilities. Funding relies on equity raises and convertible notes, with future disclosures on cash generation and commercial traction being critical for its financial sustainability.
Revvity stock (US76155R1086): Q1 earnings beat with $1.06 EPS
Revvity Inc. reported Q1 2026 adjusted EPS of $1.06, surpassing analyst estimates by $0.04. The stock traded at $96.67 on the NYSE, reflecting a 1.75% intraday increase and a market capitalization of $10.81 billion. The company's performance is further bolstered by a previously authorized $1 billion share repurchase program.
RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone Assay
Revvity, Inc. (RVTY) announced that its subsidiary, Immunodiagnostic Systems (IDS), received FDA clearance for its Total Testosterone automated chemiluminescence immunoassay (ChLIA). This new assay, alongside existing FDA-cleared tests for free testosterone and sex hormone-binding globulin, creates a comprehensive automated testosterone testing solution on a single platform, enhancing diagnostic capabilities for androgen-related conditions in both men and women. Despite a recent dip in share price, this expansion is expected to strengthen Revvity's position in the growing endocrine diagnostics market, which is projected to reach $15.69 billion by 2026.
Revvity Inc. stock outperforms competitors on strong trading day
Shares of Revvity Inc. (RVTY) increased by 1.44% to $96.38 on Thursday, outperforming the broader market indices, with the S&P 500 Index and Dow Jones Industrial Average also seeing gains. Despite this rise, the stock remains 18.53% below its 52-week high of $118.30, achieved on January 22nd. The article highlights Revvity's strong performance on a positive trading day for the stock market.
RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone Assay
Revvity, Inc. (RVTY) announced that its subsidiary, Immunodiagnostic Systems (IDS), received FDA clearance for its Total Testosterone automated chemiluminescence immunoassay (ChLIA). This approval expands Revvity's endocrine diagnostics portfolio, offering a comprehensive automated testosterone testing solution alongside existing assays for free testosterone and SHBG. The company expects the clearance to strengthen its market position, especially given the anticipated growth in the endocrine testing market.
Earnings Update: Here's Why Analysts Just Lifted Their AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target To US$10.14
AbCellera Biologics Inc. (NASDAQ:ABCL) recently reported strong earnings, with revenues exceeding analyst forecasts by 42% and statutory losses being smaller than anticipated. Following these results, analysts have modestly increased their revenue predictions and reduced loss per share forecasts for 2026, leading to an 11% rise in the consensus price target to US$10.14. Despite the improved sentiment, the company is still projected to experience a significant revenue reduction of 61% in 2026 and a decline worse than the broader industry.
Revvity secures FDA clearance for total testosterone immunoassay
Revvity has received FDA clearance for its total testosterone automated chemiluminescence immunoassay (ChLIA) through its Immunodiagnostic Systems (IDS) subsidiary. This new assay, along with existing FDA-cleared tests for free testosterone and SHBG, now provides a fully integrated solution for diagnosing testosterone-related disorders on a single platform. The automated approach aims to simplify laboratory workflows and improve diagnostic efficiency by eliminating the need for complex legacy methods like ED-LC/MS.
Revvity secures FDA clearance for total testosterone immunoassay
Revvity has received FDA clearance for its total testosterone automated chemiluminescence immunoassay (ChLIA) through its Immunodiagnostic Systems (IDS) subsidiary. This new assay, alongside existing tests for free testosterone and sex hormone-binding globulin (SHBG), offers a fully integrated diagnostic approach for testosterone-related disorders on a single platform. This advancement aims to streamline workflow and centralize diagnostics for identifying suspected hypogonadism in men, replacing complex legacy methods.
Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution
Revvity, through its subsidiary Immunodiagnostic Systems (IDS), announced FDA clearance for its Total Testosterone automated chemiluminescence immunoassay (ChLIA). This assay completes their testosterone testing portfolio, which now offers direct ChLIA measurements for total testosterone, free testosterone, and sex hormone-binding globulin on a single platform. This integrated solution streamlines diagnostic testing for androgen-related conditions in both men and women, replacing more complex manual methods.
Revvity stock (US76155R1086): FDA clearance for testosterone assay, Q1 earnings beat
Revvity received FDA clearance for its total testosterone assay, expanding its automated testing solutions. This comes after the company reported strong Q1 2026 earnings, with revenue up 7% to $711.1 million and EPS of $1.06, beating analyst estimates. The company's stock, listed on NYSE under RVTY, trades at $98.74 and is up 2% year-to-date, indicating solid operational momentum and financial resilience.
Revvity Inc. stock underperforms Wednesday when compared to competitors
Revvity Inc. (RVTY) stock fell 4.32% on Wednesday, closing at $95.01, despite a mixed trading session where the S&P 500 Index rose. The company's shares are now 19.69% below their 52-week high achieved in January. This underperformance was noted against its competitors on a day where the Dow Jones Industrial Average slightly declined.
FDA Clears Revvity Total Testosterone Assay for Automated Testing
Revvity Inc., through its subsidiary Immunodiagnostic Systems, has received FDA clearance for its Total Testosterone automated chemiluminescence immunoassay (ChLIA). This new assay, along with existing tests for free testosterone and sex hormone-binding globulin (SHBG), provides a comprehensive solution for diagnosing testosterone-related disorders on a single platform. The integrated system aims to streamline clinical workflows by offering direct measurements and replacing complex equilibrium dialysis-liquid chromatography/mass spectrometry (ED-LC/MS) methods.
Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution
Revvity, through its subsidiary Immunodiagnostic Systems (IDS), has received FDA clearance for its Total Testosterone automated chemiluminescence immunoassay (ChLIA). This assay, combined with their existing FDA-cleared tests for free testosterone and sex hormone-binding globulin (SHBG), creates a comprehensive, first-of-its-kind solution for testosterone-related disorders on a single platform. The expanded portfolio simplifies clinical workflows by enabling direct ChLIA measurements, replacing complex and less reproducible methods without compromising accuracy.
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently purchased between $1,001 and $15,000 worth of BridgeBio Pharma, Inc. (NASDAQ:BBIO) stock on April 29th, according to a May 8th filing. This insider buying comes amidst mixed sentiment for the biotech company, which recently reported Q1 revenue of $194.52 million, beating estimates, despite an EPS miss and a notable share sale by its CEO. Analysts, however, maintain a "Moderate Buy" rating with a consensus target of $88.19 for BBIO.
Revvity (RVTY) director Michael Klobuchar receives new restricted stock unit grants
Revvity (RVTY) director Michael A. Klobuchar recently received two grants of restricted stock units (RSUs) totaling 2,280 shares, not through open-market transactions. These RSUs are scheduled to fully vest on April 27, 2027, provided his continued service or earlier under specific conditions such as death, disability, or a qualifying retirement. After these grants, his direct holdings in Revvity common stock amount to 7,368 shares.
REVVITY (RVTY) director granted new restricted stock unit awards
REVVITY, INC. director Sophie V. Vandebroek was granted 2,280 restricted stock units in two awards (1,265 and 1,015 units), which will vest on April 27, 2027, provided she remains with the company. These restricted stock units represent a contingent right to receive common stock at no cash cost as part of her equity compensation. The vesting can be accelerated under specific conditions such as death, disability, qualifying retirement, or termination within 12 months following a change in control.
Revvity stock (US76155R1086): Q1 earnings beat and analyst upgrade drive gains
Revvity (US76155R1086) reported strong Q1 2026 earnings, with EPS of $1.06 surpassing estimates and revenue increasing 7% year-over-year. Following the announcement, the stock rose 0.31% to $101.32 on the NYSE. Despite a consensus 'Hold' rating from analysts and a mixed sentiment, the company maintains a strong position in the life sciences and diagnostics sectors.
Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Kraft Heinz Company (NASDAQ:KHC)
Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold between $1,001 and $15,000 in Kraft Heinz (NASDAQ:KHC) shares on April 14th, with the transaction reported on May 8th. This insider trade follows Kraft Heinz's strong quarterly earnings, where the company surpassed analyst expectations with $0.58 EPS and $6.05 billion in revenue. Despite a consensus "Reduce" rating from Wall Street analysts, Kraft Heinz announced a quarterly dividend of $0.40 per share, offering an annualized yield of approximately 6.9%.
EPAM Systems (NYSE:EPAM) Stock Unloaded Rep. Gilbert Ray Cisneros, Jr.
Representative Gilbert Ray Cisneros, Jr. sold shares of EPAM Systems (NYSE:EPAM) worth between $1,001 and $15,000 on April 14th. This transaction comes as EPAM Systems reported better-than-expected quarterly results, with EPS of $2.86 and revenue of $1.40 billion, marking a 7.6% year-over-year increase. Despite the strong earnings, analyst sentiment remains cautious, with a consensus "Hold" rating and an average price target of $155.50.
Rep. Gilbert Ray Cisneros, Jr. Buys Verizon Communications Inc. (NYSE:VZ) Stock
Rep. Gilbert Ray Cisneros, Jr. (Democratic-California) recently purchased between $1,001 and $15,000 worth of Verizon Communications Inc. (NYSE:VZ) stock on April 14, 2026, according to a May 8 filing. Verizon reported Q1 earnings of $1.28 per share, beating estimates, with revenue of $34.44 billion, slightly below expectations, and reaffirmed its full-year 2026 EPS guidance of $4.95-$4.99. Wall Street analysts maintain a "Moderate Buy" consensus rating for Verizon with a price target around $50.59.
Rep. Gilbert Ray Cisneros, Jr. Buys LPL Financial Holdings Inc. (NASDAQ:LPLA) Shares
Rep. Gilbert Ray Cisneros, Jr. (Democrat-California) recently purchased between $1,001 and $15,000 worth of LPL Financial Holdings Inc. (NASDAQ:LPLA) shares. This transaction, dated April 6th, was part of several trades made by the Representative, despite LPL Financial's stock trading below its 50-day and 200-day moving averages. The company recently reported better-than-expected quarterly earnings but slightly missed revenue forecasts, and analysts currently rate the stock as a "Moderate Buy."
Rep. Gilbert Ray Cisneros, Jr. Sells SS&C Technologies Holdings, Inc. (NASDAQ:SSNC) Stock
Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold between $1,001 and $15,000 worth of SS&C Technologies Holdings, Inc. (NASDAQ:SSNC) stock on April 13th, as disclosed in a May 8th filing. This sale comes as SS&C Technologies recently beat quarterly earnings expectations with $1.69 EPS and $1.65 billion in revenue, an 8.8% increase year-over-year. Despite the stock trading near its 52-week low and down 2.5%, analysts maintain a "Moderate Buy" consensus with an average price target of $96.13.
